Looking At Amgen's Recent Unusual Options Activity
Looking At Amgen's Recent Unusual Options Activity
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 13 unusual trades.
金融巨頭對安進採取了明顯的看跌舉動。我們對安進（納斯達克股票代碼：AMGN）期權歷史的分析顯示了13筆不尋常的交易。
Delving into the details, we found 46% of traders were bullish, while 53% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $1,065,054, and 3 were calls, valued at $142,121.
深入研究細節，我們發現46％的交易者看漲，而53％的交易者表現出看跌傾向。在我們發現的所有交易中，有10筆是看跌期權，價值爲1,065,054美元，3筆是看漲期權，價值爲142,121美元。
Projected Price Targets
預計價格目標
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $140.0 to $470.0 for Amgen during the past quarter.
分析這些合約的交易量和未平倉合約，大型企業似乎一直在關注安進在過去一個季度的價格範圍從140.0美元到470.0美元不等。
Analyzing Volume & Open Interest
分析交易量和未平倉合約
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 326.67 with a total volume of 602.00.
就流動性和利息而言，今天安進期權交易的平均未平倉合約爲326.67，總交易量爲602.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $140.0 to $470.0 over the last 30 days.
在下圖中，我們可以跟蹤過去30天在140.0美元至470.0美元行使價區間內的安進大額資金交易的看漲和看跌期權交易量和未平倉合約的變化。
Amgen 30-Day Option Volume & Interest Snapshot
安進 30 天期權交易量和利息快照
Biggest Options Spotted:
發現的最大選擇：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BULLISH | 01/17/25 | $58.55 | $56.95 | $58.2 | $320.00 | $232.8K | 1.0K | 112 |
| AMGN | PUT | SWEEP | BULLISH | 01/17/25 | $58.25 | $57.0 | $58.2 | $320.00 | $174.6K | 1.0K | 112 |
| AMGN | PUT | SWEEP | BEARISH | 01/17/25 | $57.95 | $57.95 | $57.95 | $320.00 | $173.8K | 1.0K | 0 |
| AMGN | PUT | SWEEP | BEARISH | 01/17/25 | $57.9 | $57.9 | $57.9 | $320.00 | $162.1K | 1.0K | 32 |
| AMGN | PUT | TRADE | NEUTRAL | 01/17/25 | $58.95 | $56.65 | $57.9 | $320.00 | $69.4K | 1.0K | 72 |
| 符號 | 看跌/看漲 | 交易類型 | 情緒 | Exp。日期 | 問 | 出價 | 價格 | 行使價 | 總交易價格 | 未平倉合約 | 音量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 放 | 掃 | 看漲 | 01/17/25 | 58.55 美元 | 56.95 美元 | 58.2 美元 | 320.00 美元 | 232.8 萬美元 | 1.0K | 112 |
| AMGN | 放 | 掃 | 看漲 | 01/17/25 | 58.25 美元 | 57.0 美元 | 58.2 美元 | 320.00 美元 | 174.6 萬美元 | 1.0K | 112 |
| AMGN | 放 | 掃 | 粗魯的 | 01/17/25 | 57.95 美元 | 57.95 美元 | 57.95 美元 | 320.00 美元 | 173.8 萬美元 | 1.0K | 0 |
| AMGN | 放 | 掃 | 粗魯的 | 01/17/25 | 57.9 美元 | 57.9 美元 | 57.9 美元 | 320.00 美元 | 162.1 萬美元 | 1.0K | 32 |
| AMGN | 放 | 貿易 | 中立 | 01/17/25 | 58.95 美元 | 56.65 美元 | 57.9 美元 | 320.00 美元 | 69.4 萬美元 | 1.0K | 72 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是基於生物技術的人體療法領域的領導者。旗艦藥物包括紅細胞增強劑 Epogen 和 Aranesp、免疫系統增強劑 Neupogen 和 Neulasta，以及用於炎症性疾病的 Enbrel 和 Otezla。安進於2006年推出了其首款癌症治療藥物Vectibix，並推出了強健骨骼的藥物Prolia/Xgeva（2010年獲得批准）和Evenity（2019年）。對Onyx的收購增強了該公司通過Kyprolis的治療腫瘤學產品組合。最近推出的產品包括Repatha（降膽固醇）、Aimovig（偏頭痛）、Lumakras（肺癌）和Tezspire（哮喘）。2023年對Horizon的收購帶來了幾種罕見病藥物，包括甲狀腺眼病藥物Tepezza。安進的生物仿製藥產品組合也在不斷增長。
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
鑑於安進最近的期權歷史，現在應該將重點放在公司本身上。我們的目標是探索其目前的表現。
Amgen's Current Market Status
安進目前的市場地位
- With a trading volume of 528,508, the price of AMGN is down by -0.79%, reaching $267.86.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 20 days from now.
- AMGN的交易量爲528,508美元，價格下跌了-0.79％，至267.86美元。
- 當前的RSI值表明，該股目前在超買和超賣之間處於中立狀態。
- 下一份收益報告定於20天后發佈。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期權交易具有更高的風險和潛在的回報。精明的交易者通過不斷自我教育、調整策略、監控多個指標以及密切關注市場走勢來管理這些風險。藉助Benzinga Pro的實時警報，隨時了解最新的安進期權交易。
譯文內容由第三人軟體翻譯。